Clinical utility of 18F-DOPA-PET in movement disorders. A systematic review;Utilidad clínica de la 18FDOPA-PET en trastornos del movimiento. Una revisión sistemática

Revista Espanola de Medicina Nuclear

Volumn 28, Issue 3, 2009, Pages 106-113

  Punal Rioboo J ^a   Serena Puig, A ^b   Varela Lema, L ^a   Alvarez Paez A M ^b   Ruano Ravina, A ^a,c,d  

^a Agencia de Evaluación de Tecnologías Sanitarias de Galicia Avalia t   (Spain)

^b HOSPITAL DO MEIXOEIRO   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

18F DOPA; Movement disorders; Parkinsonism; PET; Positron emission tomography; Systematic review

Indexed keywords

6 FLUORODOPA F 18; CARBIDOPA;

ARTICLE; CAUDATE NUCLEUS; COGNITIVE DEFECT; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FRONTAL CORTEX; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PROGRESSIVE SUPRANUCLEAR PALSY; PUTAMEN; SHY DRAGER SYNDROME; SYSTEMATIC REVIEW;

ADULT; AGED; AGED, 80 AND OVER; CAUDATE NUCLEUS; COGNITION DISORDERS; CORPUS STRIATUM; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; DIHYDROXYPHENYLALANINE; DISEASE PROGRESSION; FEMALE; FLUORINE RADIOISOTOPES; FRONTAL LOBE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PUTAMEN; RADIOPHARMACEUTICALS; REGISTRIES;

EID: 67649215251     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/S0212-6982(09)71352-7     Document Type: Article

References (38)

1. Von Campenhausen S., Bornschein B., Wick R., Bötzel K., Sampaio C., and Poewe W. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 15 (2005) 473-490
2. Scrag A., Ben-Shlomo Y., and Quinn N.P. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 354 (1999) 1771-1775
3. Griffiths C., and Rooney C. Trends in mortality from Alzheimer's disease, Parkinson's disease and demencia, England and Wales, 1979-2004. Health Stat Q 30 (2006) 6-14
4. Nath U., Thomson R., Wood R., Ben-Shlomo Y., Lees A., and Rooney C. Population based mortality and quality of death certification in progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome. J Neurol Neurosurg Psychiatry 76 (2005) 498-502
5. Estorch M., Camacho V., Fuertes J., Rodríguez-Revuelto A., Hernández M.A., Flotats A., et al. Demencia con cuerpos de Lewy y enfermedad de Alzheimer: diagnóstico diferencial mediante estudio de la inervación simpática cardiaca con MIBG. Rev Esp Med Nucl 25 (2006) 229-235
6. Ortega Lozano S.J., Martínez Del Valle Torres M.D., Jiménez-Hoyuela García J.M., Gutiérrez Cardo A.L., and Campos Arillo V. Utilidad diagnóstica de la SPECT con FP-CIT en el estudio de pacientes con parkinsonismo. Rev Esp Med Nucl 26 (2007) 277-285
7. Collantes M., Peñuelas I., Álvarez-Erviti L., Blesa J., Martí-Climent J.M., Quincoces G., et al. Utilización de la 11C-(+)-α -dihidrotetrabenazina para la evaluación de la inervación dopaminérgica en modelos animales de la enfermedad de Parkinson. Rev Esp Med Nucl 27 (2008) 103-111
8. Quincoces G., Collantes M., Catalán R., Ecay M., Prieto E., Martino E., et al. Síntesis rápida y simplificada de 11C-(+)-α -dihidrotetrabenazina para su utilización como radioligando PET de los transportadores vesiculares de monoaminas. Rev Esp Med Nucl 27 (2008) 13-21
9. Puñal Riobóo J., Varela Lema L., Serena Puig A., and Ruano-Ravina A. Efectividad del 123I-ioflupano (DaTSCAN) en el diagnóstico de síndromes parkinsonianos. Una revisión sistemática. Rev Esp Med Nucl 26 (2007) 375-384
10. Cropley V.L., Fujita M., Bara-Jiménez W., Brown A.K., Zhang X.Y., Sangare J., et al. Preand post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res 15 163 (2008) 171-182
11. Hilker R., Schweitzer K., Coburger S., Ghaemi M., Weisenbach S., and Jacobs A.H. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 Activity. Arch Neurol 62 (2005) 378-382
12. Eidelberg D., Moeller J.R., Dhawan V., Sidtis J.J., Ginos J.Z., Strother S.C., et al. The Metabolic Anatomy of Parkinson's Disease: Complementary [18F]Fluorodopa Positron Emission Tomograhic Studies. Mov Disord 5 (1990) 203-213
13. Morrish P.K., Sawle G.V., and Brooks D.J. Clinical and [18F] dopa PET finding in early Parkinson's disease. J Neurol Neurosurg Psychiatry 59 (1995) 597-600
14. Brooks D.J., Ibanez V., Sawle G., Quinn N., Lees A.J., Mathias C.J., et al. Diferenting patterns of striatal 18FDopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 28 (1990) 547-555
15. Nurmi E., Ruottinen H.M., Bergman J., Haaparanta M., Solin O., and Sonninen P. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 16 (2001) 608-615
16. Rinne J.O., Portin R., Ruottinen H.M., Nurmi E., Bergman J., and Haaparanta M. Cognitive impairment and the brain dopaminergic system in Pakinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol 57 (2000) 470-475
17. Brück A., Aalto S., Nurmi E., Bergman J., and Rinne J.O. Cortical 6-[(18)F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol Aging 26 (2005) 891-898
18. Ito K., Nagano-Saito A., Kato T., Arahata Y., Nakamura A., and Kawasumi Y. Striatal and extrastriatal dysfunction in Parkison's disease with demencia: A 6-[(18)F]fluoro- L-dopa PET study. Brain 125 (2002) 1358-1365
19. Sawle G.V., Playford E.D., Burn D.J., Cunningham V.J., and Brooks D.J. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. Arch Neurol 51 (1994) 237-243
20. Vingerhoets F.J.G., Snow B.J., Lee C.S., Schulzer M., Mak E., and Calne D.B. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 36 (1994) 759-764
21. Morrish P.K., Rakshi J.S., Bailey D.L., Sawle G.V., and Brooks D.J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64 (1998) 314-319
22. Nagasawa H., Saito H., Kogure K., Hatazawa J., Itoh M., Fujiwara T., et al. 6- [18F]Fluorodopa metabolism in patients with hemiparkinsonism studied by positron emission tomography. J Neurol Sci 115 (1993) 136-143
23. Morrish P.K., Sawle G.V., and Brooks D.J. Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. Brain 119 (1996) 2097-2103
24. Kish S.J., Shannak K., and Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 318 (1988) 876-880
25. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substancia nigra regional selectivity. Brain 114 (1991) 2283-2301
26. Kish S.J., Chang L.J., Mirchandani L., Shannak K., and Hornykiewicz O. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia and brain neurotransmitter markers. Ann Neurol 18 (1985) 530-536
27. Ruberg M., Javoy-Agid F., Hirsh E., Scatton B., Lheureux R., Hauw J.J., et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 18 (1985) 523-529
28. Jellinger K., Riederer P., and Tomanaga M. Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neurol Transmission Suppl 16 (1980) 111-128
29. Spokes E.G.S., Bannister R., and Oppenheimer D.R. Multiple system atrophy with autonomic failure. Clinical, histological, and neurochemical observations on four cases. J Neurol Sci 43 (1979) 59-62
30. Duncan J., and Owen A.M. Common regions of the human frontal lober recruited by diverse cognitive demands. Trends Neurosci 23 (2000) 475-483
31. Faw B. Pre-frontal executive committee for perception, working memory, attention, long-term memory, motor control, and thinking: a tutorial review. Conscious Cogn 12 (2003) 83-139
32. Bruck A., Portin R., Lindell A., Laihinen A., Bergman J., Haaparanta M., et al. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett 311 (2001) 81-84
33. Marie R.M., Barre L., Dupuy B., Viader F., Defer G., and Baron J.C. Relationships between striatal dopamine denervation and frontal executive test in Parkinson's disease. Neurosci Lett 260 (1999) 77-80
34. Rinne J.O., Rummukainen J., Paljarvi L., and Rinne U.K. Dementia in Parkinson's disease is related to neuronal loss in the medial substancia nigra. Ann Neurol 26 (1989) 47-50
35. Reches A., and Fahn S. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 12 (1982) 267-271
36. Cedarbaum J.M., Kutt H., and McDowell F.H. Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology 38 (1988) 533-536
37. Nutt J.G., Woodward W.R., and Anderson J. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mecanism of action in the treatment of parkinsonism. Ann Neurol 18 (1985) 537-543
38. Guttman M., Léger G., Cedarbaum J.M., Reches A., Woodward W., Evans A., et al. 3-Omethyldopa administration does not after fluorodopa transport into the brain. Ann Neurol 31 (1992) 638-643